Skip to main content
SpringerLink
Log in

Evidenzbasierte Pharmakologische Harnsteinmetaphylaxe

Evidence-based pharmacological metaphylaxis of stone disease

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Rund ein Viertel der Steinbildner sind hinsichtlich einer rezidivierenden Urolithiasis bzw. hochaktiven metabolischen Störung tatsächliche Hochrisikopatienten. Sie benötigen als adäquate Therapie bzw. zur Sekundärprävention eine spezifische Metaphylaxe, die sich an der metabolischen Risikosituation orientiert. Die aktuellen Therapieempfehlungen für die einzelnen Harnsteinarten werden in diesem Beitrag kurz skizziert und im Hinblick ihrer Evidenzgrundlage bewertet. Außerdem wird ein Follow-up für pharmakologisch therapierte Hochrisikosteinbildner vorgestellt.

Abstract

Approximately one-fourth of urolithiasis patients are at high risk for recurrent stone formation or severe metabolic disturbances. These patients need specific metaphylaxis for effective stone prevention, adjusted to their individual metabolic risk. Recent recommendations for the pharmacological treatment of stone diseases are summarized in this article. For the different treatment options, evidence from the literature was assessed. In addition, a follow-up concept for pharmacologically treated high-risk stone formers is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abdulhadi MH, Hall PM, Streem SB (1993) Can citrate therapy prevent nephrolithiasis? Urology 41: 221–224

    Article  PubMed  Google Scholar 

  2. Allerheiligen DA, Schoeber J, Houston RE et al. (1998) Hyperparathyroidism. Am Fam Phys 57: 1795–1798

    Google Scholar 

  3. Asper R, Schmucki O (1982) Cystinuria therapy by ascorbic acid (author’s transl). Urol Int 37: 91–109

    PubMed  Google Scholar 

  4. Barbey F, Joly D, Rieu P et al. (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163: 1419–1423

    Article  PubMed  Google Scholar 

  5. Barcelo P, Wuhl O, Servitge E et al. (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150: 1761–1764

    PubMed  Google Scholar 

  6. Berio A, Piazzi A (2001) Prophylaxia of cystine calculosis by alpha-mercaptopropionyl-glycine administered continuously or every other day. Boll Soc Ital Biol Sper 77: 35–41

    PubMed  Google Scholar 

  7. Bilobrov VM, Chugaj AV (1993) Physicochemical background for ambiguity of clinical recommendations in treating phosphate nephrolithiasis. Urol Int 50: 43–46

    PubMed  Google Scholar 

  8. Birwe H, Schneeberger W, Hesse A (1991) Investigations of the efficacy of ascorbic acid therapy in cystinuria. Urol Res 19: 199–201

    Article  PubMed  Google Scholar 

  9. Blair B, Fabrizio M (2000) Pharmacology for renal calculi. Expert Opin Pharmacother 1: 435–441

    Article  PubMed  Google Scholar 

  10. Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22 [Suppl 6]: 78–86

    Article  Google Scholar 

  11. Butz M (1987) Alkalizitrat-Therapie bei rezidivierender Kalzium-Urolithiasis. Urologe B 27: 95–99

    Google Scholar 

  12. Cochat P, Gaulier JM, Koch Nogueira PC et al. (1999) Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur J Pediatr 158 [Suppl 2]: 75–80

    Article  Google Scholar 

  13. Cohen TD, Streem SB, Hall P (1995) Clinical effect of captopril on the formation and growth of cystine calculi. J Urol 154: 164–166

    Article  PubMed  Google Scholar 

  14. de Pauw L, Gelin M, Danpure CJ et al. (1990) Combined liver-kidney transplantation in primary hyperoxaluria type 1. Transplantation 50: 886–887

    PubMed  Google Scholar 

  15. Domrongkitchaiporn S, Khositseth S, Stitchantrakul W et al. (2002) Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Am J Kidney Dis 39: 383–391

    PubMed  Google Scholar 

  16. Esen T, Marshall VR, Rao N, Ettinger B (2003) Medical management of urolithiasis, chap. 4. In: Segura JW, Conort P, Khoury S, Pak CY, Preminger GM, Tolley D (eds) Stone disease, 1 edn. Health Publications, Paris, pp 133–149

  17. Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139: 679–684

    PubMed  Google Scholar 

  18. Ettinger B, Pak CY, Citron JT et al. (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158: 2069–2073

    Article  PubMed  Google Scholar 

  19. Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG (2001) A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol Res 29: 295–302

    Article  PubMed  Google Scholar 

  20. Gault MH, Parfrey PS, Robertson WG (1988) Idiopathic calcium phosphate nephrolithiasis. Nephron 48: 265–273

    PubMed  Google Scholar 

  21. Hautmann R, Terhorst B, Stuhlsatz HW, Lutzeyer W (1977) Mercaptopropionylglycine: a progress in cystine stone therapy. J Urol 117: 628–630

    PubMed  Google Scholar 

  22. Hesse A (2002) Urinary calculi: 1. Epidemiology, laboratory diagnosis, genetics and infections. Urologe A 41: 496–506

    Article  PubMed  Google Scholar 

  23. Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17: 308–315

    Article  PubMed  Google Scholar 

  24. Hesse A, Miersch WD, Classen A et al. (1988) 2,8-Dihydroxyadeninuria: laboratory diagnosis and therapy control. Urol Int 43: 174–178

    PubMed  Google Scholar 

  25. Hesse A, Siener R, Heynck H, Jahnen A (1993) The influence of dietary factors on the risk of urinary stone formation. Scann Microsc 7: 1119–1127

    Google Scholar 

  26. Hesse A, Tiselius HG, Jahnen A (2002) Urinary stones, 2nd edn. Karger, Basel

  27. Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis – a prospective randomized study. Br J Urol 73: 362–365

    PubMed  Google Scholar 

  28. Holmes RP (1998) Pharmacological approaches in the treatment of primary hyperoxaluria. J Nephrol 11 [Suppl 1]: 32–35

    PubMed  Google Scholar 

  29. Hoppe B, Langman CB (2003) A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 18: 986–991

    Article  PubMed  Google Scholar 

  30. Hoppe B, Latta K, von Schnakenburg C, Kemper MJ (2005) Primary hyperoxaluria – the German experience. Am J Nephrol 25: 276–281

    Article  PubMed  Google Scholar 

  31. Jacobs D, Heimbach D, Hesse A (2001) Chemolysis of struvite stones by acidification of artificial urine – an in vitro study. Scand J Urol Nephrol 35: 345–349

    Article  PubMed  Google Scholar 

  32. Jarrar K, Boedeker RH, Weidner W (1996) Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris) 30: 112–117

    Google Scholar 

  33. Jendle-Bengten C, Tiselius HG (2000) Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol 34: 36–41

    Article  PubMed  Google Scholar 

  34. Kato Y, Yamaguchi S, Yachiku S et al. (2004) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 63: 7–11

    Article  PubMed  Google Scholar 

  35. Kearns AE, Thompson GB (2002) Medical and surgical management of hyperparathyroidism. Mayo Clin Proc 77: 87–91

    PubMed  Google Scholar 

  36. Khan SR, Shevock PN, Hackett RL (1993) Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J Urol 149: 412–416

    PubMed  Google Scholar 

  37. Knoll T, Janitzky V, Michel MS et al. (2003) Cystinuria – Cystine stones: Recommendations for diagnosis, therapy and follow-up. Aktuelle Urol 34: 97–101

    Article  PubMed  Google Scholar 

  38. Kohri K, Tozawa K, Hayashi Y et al. (2000) Clinical features of primary hyperparathyroidism: preoperative localization and parathyroidectory. Biomed Pharmacother 54 [Suppl 1]: 69–71

    Article  PubMed  Google Scholar 

  39. Kollars J, Zarroug AE, van Heerden J et al. (2005) Primary hyperparathyroidism in pediatric patients. Pediatrics 115: 974–980

    Article  PubMed  Google Scholar 

  40. Laerum E (1984) Metabolic effects of thiazide versus placebo in patients under long-term treatment for recurrent urolithiasis. Scand J Urol Nephrol 18: 143–149

    PubMed  Google Scholar 

  41. Leskovar P (1980) Current status of prevention and therapy of urinary calculi and peroral chemo-litholysis with special attention to the relationship of increased excretion of uric acid in oxalate lithiasis. Z Urol Nephrol 73: 229–239

    PubMed  Google Scholar 

  42. Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7: 207–211

    Article  PubMed  Google Scholar 

  43. Leumann E, Hoppe B, Neuhaus T, Blau N (1995) Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 10 [Suppl 8]: 14–16

    Google Scholar 

  44. Lindell A, Denneberg T, Hellgren E et al. (1995) Clinical course and cystine stone formation during tiopronin treatment. Urol Res 23: 111–117

    Article  PubMed  Google Scholar 

  45. Ohkawa M, Tokunaga S, Nakashima T et al. (1992) Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 69: 571–576

    PubMed  Google Scholar 

  46. Osborne CA, Lulich JP, Bartges JW et al. (1999) Drug-induced urolithiasis. Vet Clin North Am Small Anim Pract 29: 251–266

    PubMed  Google Scholar 

  47. Pak CY (1991) Citrate and renal calculi: New insights and future directions. Am J Kidney Dis 17: 420–425

    PubMed  Google Scholar 

  48. Pak CY, Fuller C, Sakhaee K et al. (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136: 1003–1008

    PubMed  Google Scholar 

  49. Pak CY, Sakhaee K, Fuller C (1986) Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30: 422–428

    PubMed  Google Scholar 

  50. Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13: 679–685

    PubMed  Google Scholar 

  51. Preminger GM (1987) Pharmacologic treatment of uric acid calculi. Urol Clin North Am 14: 335–338

    PubMed  Google Scholar 

  52. Preminger GM, Sakhaee K, Skurla C, Pak CY (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134: 20–23

    PubMed  Google Scholar 

  53. Rodman JS (1991) Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts. J Urol 145: 97–99

    PubMed  Google Scholar 

  54. Rodman JS (1999) Struvite stones. Nephron 81 [Suppl 1]: 50–59

    Article  PubMed  Google Scholar 

  55. Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60: 378–382

    Article  PubMed  Google Scholar 

  56. Rodman JS, Mahler RJ (2000) Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am 27: 275–285

    Article  PubMed  Google Scholar 

  57. Schneeberger W, Hesse A, Vahlensieck W (1992) Recurrent nephrolithiasis in renal tubular acidosis. Metabolic profiles, therapy and course. Urol Res 20: 98–100

    Article  PubMed  Google Scholar 

  58. Shekarriz B, Stoller ML (2002) Uric acid nephrolithiasis: current concepts and controversies. J Urol 168: 1307–1314

    Article  PubMed  Google Scholar 

  59. Siener R, Hesse A (2003) The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. Eur J Nutr 42: 332–337

    Article  PubMed  Google Scholar 

  60. Simmonds HA (1986) 2,8-Dihydroxyadenine lithiasis. Clin Chim Acta 160: 103–108

    Article  PubMed  Google Scholar 

  61. Straub M, Hautmann RE, Hesse A, Rinnab L (2005) Calcium oxalate stones and hyperoxaluria What is certain? What is new? Urologe A 44(11): 1315–1323

    Article  PubMed  Google Scholar 

  62. Straub M, Strohmaier WL, Berg W et al. (2005) Diagnosis and metaphylaxis of stone disease Consensus concept of the National Working Committee on Stone Disease for the Upcoming German Urolithiasis Guideline. World J Urol 23: 309–323

    Article  PubMed  Google Scholar 

  63. Streem SB, Cohen TD, Hall P (1996) Efficacy of captopril on formation and growth of cystine calculi. In: Tiselius HG (ed) Renal stones. Tiselius, Linkoping, pp 168–170

  64. Trinchieri A, Luongo P, Rovera F et al. (1994) Treatment of cystine nephrolithiasis with alpha-mercaptopropionylglycine. In: Ryall R (ed) Urolithiasis, 2nd edn. Plenum Press, New York, pp 603–604

  65. Watts RW, Morgan SH, Danpure CJ et al. (1991) Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med 90: 179–188

    PubMed  Google Scholar 

  66. Yendt ER, Cohanim M (1985) Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. N Engl J Med 312: 953–957

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik, Universitätsklinikum Ulm, Deutschland

    R. E. Hautmann

  2. Urologische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Deutschland

    M. Straub

Authors
  1. M. Straub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. E. Hautmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Straub.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Straub, M., Hautmann, R.E. Evidenzbasierte Pharmakologische Harnsteinmetaphylaxe. Urologe 45, 1399–1405 (2006). https://doi.org/10.1007/s00120-006-1235-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1235-z

Schlüsselwörter

Keywords

Search

Navigation